![]() ![]() What do you want to achieve? Visit us at omm.com. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. Device, led by a 3x increase in European investment, was up 53. Vensana is actively investing in development and commercial stage companies across the medtech sector, including medical devices, diagnostics and data science. Biopharma, healthtech, dx/tools and device all showed record investment, with healthtech up 157 compared to 2020. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. 2021 was the largest healthcare fundraising year ever, surpassing 2020s record of 16.88B. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. It’s more than what you do: it’s how you do it. New York, XNCM:STSS Software Machines and Adaptive Implants in Orthopedics (SMAIO) SA, Lyon, France, XPAR:ALSMA. The O’Melveny team was led by partners Ke Geng and Ke Zhu, with support from counsel Ye Sun and Wendy Kan, and associates Claire Huang, Xiaoyu Xu, and Katherine Wang. We are also awaiting word on our CMS Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES) application for the Tablo. Med-tech IPOs in 2022 Sharps Technology Inc. The joint global coordinators also included BOC International and UBS. Morgan Stanley and Huatai International were the joint sponsors and lead underwriters. Their deep experience with the biotech industry, precise understanding of the Chapter 18A listing rules, and ability to efficiently handle complicated restructuring issues is most impressive. “O’Melveny was tremendously helpful to Peijia during the listing process. “Today’s successful listing in Hong Kong is an important milestone for the company’s development,” said Dr. Peijia Medical focuses on the high-growth interventional procedural medical device market in China. It is a leading domestic player in the transcatheter valve therapeutic medical device market, as well as the neurointerventional procedural medical device market. Peijia Medical’s IPO is the second largest IPO in Hong Kong year-to-date in size, after Akeso. The Hong Kong public offering has been oversubscribed by approximately 1,200 times, making it the most popular offering by funds frozen so far in 2020, surpassing that of Akeso Biopharma, in which O’Melveny also served as issuer’s counsel. The stock price rose by over 70% at market opening. HONG KONG-May 15, 2020-O’Melveny advised Peijia Medical Limited in its recent IPO and listing on the Hong Kong Stock Exchange. The IPO offering size was approximately HK$2.343 billion (US$302 million), prior to the exercise of the over-allotment option. Assuming full exercise of the over-allotment option, the offering size will be approximately HK$2.694 billion (US$348 million). By comparison, a Q4 2019 valuation study by Mercer Capital for the Medical Devices and Healthcare Technology sectors indicated a 3Q 2019 high multiple of 9.05x and 6.65x respectively. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |